palbociclib

palbociclib is an oral medication used for the treatment of specific types of breast cancer. It is a cyclin-dependent kinase inhibitor, specifically targeting CDK4 and CDK6, which are enzymes crucial for cell cycle progression. Developed by Pfizer, it is marketed under the brand name Ibrance and is typically used in combination with other agents like letrozole or fulvestrant for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.

Medical uses

Palbociclib is indicated in combination with an aromatase inhibitor such as letrozole for the initial treatment of postmenopausal women with estrogen receptor-positive, HER2-negative advanced breast cancer. It is also approved for use with fulvestrant in women with disease progression following endocrine therapy. These approvals are based on pivotal clinical trials including PALOMA-2 and PALOMA-3, which demonstrated significant improvement in progression-free survival. Its use is generally guided by confirmatory diagnostic testing for hormone receptor status, often conducted by institutions like the American Society of Clinical Oncology.

Adverse effects

The most common adverse reactions associated with palbociclib include neutropenia, leukopenia, fatigue, nausea, and alopecia. Severe neutropenia is a major dose-limiting toxicity, requiring regular monitoring of complete blood counts. Other notable effects can involve infections, pulmonary embolism, and interstitial lung disease. Management strategies often involve dose interruptions or reductions as outlined in the prescribing information from the U.S. Food and Drug Administration and recommendations from the National Comprehensive Cancer Network.

Pharmacology

As a selective inhibitor of cyclin-dependent kinase 4 and cyclin-dependent kinase 6, palbociclib blocks the phosphorylation of the retinoblastoma protein, leading to G1 phase arrest and inhibition of cellular proliferation in estrogen receptor-positive breast cancer cells. It is metabolized primarily in the liver by the CYP3A4 enzyme and sulfotransferase SULT2A1. Concomitant use with strong CYP3A inhibitors like clarithromycin or grapefruit juice is contraindicated due to increased exposure, as noted in its FDA label.

History

The discovery and development of palbociclib originated from research at Pfizer's La Jolla laboratories, building on foundational work in cell cycle biology. The drug received its first global approval from the U.S. Food and Drug Administration in February 2015 under the Priority Review and Breakthrough Therapy designations, based on data from the PALOMA-1 trial. Subsequent approvals followed from the European Medicines Agency and other regulatory bodies worldwide. Its development was significantly influenced by earlier research on cyclin-dependent kinases by scientists like David Beach and Charles J. Sherr.

Society and culture

Marketed as Ibrance, palbociclib has had a substantial economic impact, becoming a major revenue driver for Pfizer and a subject of discussions on drug pricing in oncology. Its approval was covered extensively by media outlets like The New York Times and presented at major conferences including the American Association for Cancer Research. Patient access programs have been implemented by various organizations, including the Cancer Support Community, to assist with costs. The drug's success has spurred further research into other CDK4/6 inhibitors such as ribociclib and abemaciclib.

Category:Antineoplastic drugs Category:Pfizer Category:Pyridopyrimidines